Results 71 to 80 of about 371 (109)

Are We Considering All the Potential Drug-Drug Interactions in Women's Reproductive Health? A Predictive Model Approach. [PDF]

Pharmaceutics
Garcia-Acero P, Henarejos-Castillo I, Sanz FJ, Sebastian-Leon P, Parraga-Leo A, Garcia-Velasco JA, Diaz-Gimeno P.   +6 more
europepmc   +1 more source

Glutathione-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study. [PDF]

Br J Clin Pharmacol, 2018
Kanhai KMS, Zuiker RGJA, Stavrakaki I, Gladdines W, Gaillard PJ, Klaassen ES, Groeneveld GJ.   +6 more
europepmc   +1 more source

Corticosteroids for treating sepsis in children and adults. [PDF]

Cochrane Database Syst Rev
Annane D, Briegel J, Granton D, Bellissant E, Bollaert PE, Keh D, Kupfer Y, Pirracchio R, Rochwerg B.   +8 more
europepmc   +1 more source

Targeted nanoliposomes for precision rheumatoid arthritis therapy: a review on mechanisms and in vivo potential. [PDF]

Drug Deliv
Girase R, Gujarathi NA, Sukhia A, Kota SSN, Patil TS, Aher AA, Agrawal YO, Ojha S, Sharma C, Goyal SN.   +9 more
europepmc   +1 more source

Revolutionizing rheumatoid arthritis therapy: the potential of lipid nanocarriers. [PDF]

RSC Adv
Alarcon JF, Karusan NR, Presciutti C, Miras J, Magana JR, Guerra-Rebollo M, Borrós S, Ahmad N, Fornaguera C.   +8 more
europepmc   +1 more source

Histoplasmosis in Immunocompromised and Immunocompetent Patients in Guadeloupe. [PDF]

J Fungi (Basel)
Lahuna C, Dequidt T, Postel-Vinay P, Peugny S, Haboub M, Markowicz S, Nicolas M.   +6 more
europepmc   +1 more source

Immunosuppressive therapy management during sepsis in kidney transplant recipients: a prospective multicenter study. [PDF]

Ann Intensive Care
Rivet V, Joseph A, Arrestier R, Calvet L, Moreau AS, Bureau C, Argaud L, Gabarre P, Zuber B, Raphalen JH, Pons S, Clere-Jehl R, Zafrani L.   +12 more
europepmc   +1 more source

Kinetics of methylprednisolone and its hemisuccinate ester

Clinical Pharmacology and Therapeutics, 1985
Methylprednisolone in the form of its hemisuccinate ester was injected intravenously in doses of 10 mg/kg and 63.1 mg. Plasma levels of methylprednisolone and of the ester were measured and their kinetics were calculated. Results indicate dose dependency in the kinetics of both. About 10% of the dose was excreted unchanged as hemisuccinate in the urine,
Hartmut Derendorf, Helmut Möllmann, P Rohdewald   +2 more
exaly   +4 more sources

Pharmacokinetics of Methylprednisolone Hemisuccinate and Methylprednisolone in Chronic Liver Disease

Journal of Clinical Pharmacology, 1993
The disposition of methylprednisolone (MP) and its prodrug hemisuccinate (MPHS) was assessed in six middle‐aged patients with chronic liver disease (CLD) and compared with six younger, healthy subjects after a single IV dose of 25.4 mg of MPHS. Blood and urine samples were collected over 12 hours.
Elizabeth A Ludwig, William J Jusko
exaly   +4 more sources